ImmunityBio Inc
IBRX
ISIN null / Valor 110468647
ImmunityBio Inc
UMushroom community rating:
About company
ImmunityBio, Inc. is a U.S.-based clinical-stage biopharmaceutical company that develops immunotherapies for cancer and infectious diseases, operating as a publicly traded entity (NASDAQ: IBRX). The firm’s research portfolio centers on immune-stimulating biologics and cell‑based approaches, most notably an IL‑15 receptor agonist known as N-803 (Anktiva), alongside programs in adoptive cell therapy and therapeutic vaccines, and it advances those candidates largely through early- and mid-stage clinical trials. ImmunityBio’s development strategy emphasizes using its immune-activating platforms in combination with existing cancer treatments, such as checkpoint inhibitors, to enhance anti-tumor responses, while pursuing clinical indications across multiple tumor types and infectious-disease applications.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
7321 M
Market cap (USD)
10,517,949
Daily traded volume (Shares)
2.755 / 2.575
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
